A
Anthony R. Mato
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 344
Citations - 9555
Anthony R. Mato is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 36, co-authored 275 publications receiving 6668 citations. Previous affiliations of Anthony R. Mato include Hackensack University Medical Center & Rutgers University.
Papers
More filters
Journal ArticleDOI
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster,Jakub Svoboda,Elise A. Chong,Sunita D. Nasta,Anthony R. Mato,Özlem Anak,Jennifer Brogdon,Iulian Pruteanu-Malinici,Vijay Bhoj,Daniel J. Landsburg,Mariusz A. Wasik,Bruce L. Levine,Simon F. Lacey,J. Joseph Melenhorst,David L. Porter,Carl H. June +15 more
TL;DR: CTL019 cells can be effective in the treatment of relapsed or refractory diffuse large B‐cell lymphoma and follicular lymphoma, and high rates of durable remission were observed, with recovery of B cells and immunoglobulins in some patients.
Journal ArticleDOI
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
James N. Kochenderfer,Mark E. Dudley,Robert O. Carpenter,Sadik H. Kassim,Jeremy J. Rose,William G. Telford,Frances T. Hakim,David Halverson,Daniel H. Fowler,Nancy M. Hardy,Anthony R. Mato,Dennis D. Hickstein,Juan Gea-Banacloche,Steven Z. Pavletic,Claude Sportes,Irina Maric,Steven A. Feldman,Brenna Hansen,Jennifer Wilder,Bazetta Blacklock-Schuver,Bipulendu Jena,Michael R. Bishop,Ronald E. Gress,Steven A. Rosenberg +23 more
TL;DR: Results show for the first time that donor-derived allogeneic anti-CD19-CAR T cells can cause regression of B-cell malignancies resistant to standard DLIs without causing GVHD.
Journal ArticleDOI
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
Tait D. Shanafelt,Xin V. Wang,Neil E. Kay,Curtis A. Hanson,Susan O'Brien,Jacqueline C. Barrientos,Diane F. Jelinek,Esteban Braggio,Jose F. Leis,Cong C. Zhang,Steven Coutre,Paul M. Barr,Amanda F. Cashen,Anthony R. Mato,Avina K. Singh,Michael P Mullane,Richard F. Little,Harry P. Erba,Richard Stone,Mark R. Litzow,Martin S. Tallman +20 more
TL;DR: The ibrutinib-rituximab regimen resulted in progression-free survival and overall survival that were superior to those with a standard chemoimmunotherapy regimen among patients 70 years of age or younger with previously untreated CLL.
Journal ArticleDOI
Ibrutinib Combined With Bendamustine and Rituximab Compared With Placebo, Bendamustine, and Rituximab for Previously Treated Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma (HELIOS): A Randomised, Double-Blind, Phase 3 Study
Asher Chanan-Khan,Paula Cramer,Fatih Demirkan,Graeme Fraser,Rodrigo Santucci Silva,Sebastian Grosicki,Aleksander Pristupa,Ann Janssens,Jiri Mayer,Nancy L. Bartlett,Marie Sarah Dilhuydy,Halyna Pylypenko,Javier Loscertales,Abraham Avigdor,Simon Rule,Diego Villa,Olga Samoilova,Panagiots Panagiotidis,Andre Goy,Anthony R. Mato,Anthony R. Mato,Miguel A. Pavlovsky,Claes Karlsson,Michelle Mahler,Mariya Salman,Steven Sun,Charles Phelps,Sriram Balasubramanian,Angela Howes,Michael Hallek +29 more
TL;DR: The HELIOS trial assessed the efficacy and safety of adding ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase (BTK), to bendamustine plus rituximab in patients with previously treated chronic lymphocytic leukaemia or small lymphocytics lymphoma and met the primary endpoint of progression-free survival.
Journal ArticleDOI
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.
Adam M. Petrich,Mitul Gandhi,Borko Jovanovic,Jorge J. Castillo,Saurabh Rajguru,David T. Yang,Khushboo A Shah,Jeremy D. Whyman,Frederick Lansigan,Francisco J. Hernandez-Ilizaliturri,Lisa X Lee,Stefan K. Barta,Shruthi Melinamani,Reem Karmali,Camille Adeimy,Scott E. Smith,Neil Dalal,Chadi Nabhan,David Peace,Julie M. Vose,Andrew M. Evens,Namrata Shah,Timothy S. Fenske,Andrew D. Zelenetz,Daniel J. Landsburg,Christina Howlett,Anthony R. Mato,Michael Jaglal,Julio C. Chavez,Judy P. Tsai,Nishitha Reddy,Shaoying Li,Caitlin Handler,Christopher R. Flowers,Jonathon B. Cohen,Jonathon B. Cohen,Kristie A. Blum,Kevin W. Song,Haowei Linda Sun,Oliver W. Press,Ryan D. Cassaday,Jesse Jaso,L. Jeffrey Medeiros,Aliyah R. Sohani,Jeremy S. Abramson +44 more
TL;DR: In this article, the authors conducted a retrospective multicenter study of the impact of baseline clinical factors, induction therapy, and stem cell transplant (SCT) on the outcomes of 311 patients with previously untreated DHL.